The eight rating agencies currently monitoring Ventyx Biosciences, Inc. (NASDAQ: VTYX) have given the stock an average recommendation of “buy,” which indicates that investors should purchase the company’s shares. This information was obtained from Bloomberg.com. A total of seven different analysts have each suggested to their respective client bases that investors purchase the stock. The average price goal that brokerages have set for the next year is $49.50 per share, and they have set this goal throughout the previous year.
Recently, a variety of research companies have shown interest in VTYX due to the company’s performance. On Thursday, November 17, Morgan Stanley issued a research report that signaled the beginning of the firm’s coverage of Ventyx Biosciences. The report was the first step in the company’s coverage of the company. They gave the company an “overweight” rating and anticipated a price of $45.00 for its stock in the future. The research note written by the Goldman Sachs Group and published on December 19 stated that the company would be covering Ventyx Biosciences. They suggested investing in the stock and established a price objective of $50 per share for the company.
NASDAQ: VTYX was first available for trading on Tuesday with an opening price of $34.77. Over the past 52 weeks, the price of Ventyx Biosciences has ranged from $9.50 to $41.29 at its highest point. The current price is $41.29. The stock price has reached $29.73, which corresponds to its 50-day moving average, and $26.32, which corresponds to its 200-day moving average.
On November 3, shareholders and interested parties were given access to the most recent quarterly earnings report provided by Ventyx Biosciences (NASDAQ: VTYX). Earnings per share for the company came in at $0.59 for the quarter, which was significantly lower than the consensus estimate among industry analysts, which was $0.45. Equity analysts have projected that Ventyx Biosciences will have earnings of -1.99 cents per share for the current fiscal year. This information comes from the company’s most recent quarterly report.
Christopher W. Krueger, an employee with Ventyx Biosciences, sold 50,000 shares of the company’s stock on Friday, December 2. This was covered in a report that was published on its own. Following its purchase at $1,450,500, the stock was eventually auctioned at an average price of $29.01. Following the completion of the transaction, the corporate